Abstract: Dyslipidemia refers to abnormalities in the composition, concentration, or size of lipids and lipoproteins in the circulation, and it is a key modifiable risk factor for cardiovascular (…
In a landmark FDA ruling, Ocrevus became the first DMT approved for the treatment of PP-MS in March 2017. Although the drug’s efficacy appears more modest than in patients with relapsing forms of…
Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States. Its novel B-cell-depleting mechanism offers…
MARKET OUTLOOK Sepsis is a life-threatening organ dysfunction resulting from a dysregulated host response to infection. It is one of the leading causes of death among developed countries, with…
Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary…
Venclexta (Wave 3) is the third in a multiwave series designed to track physician perception and uptake of as well as the competitive environment for the newly launched chronic lymphocytic leukemia…
Atopic Dermatitis | Emerging Therapies | Eucrisa | USis a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data…
Pulmonary hypertension (PH), particularly pulmonary arterial hypertension (PAH), is a rare but life-threatening disorder. Commercial interest in PH/PAH has increased recently due to significant…
Amyotrophic lateral sclerosis (ALS) is a degenerative disorder of motor neurons that leads to progressive muscle wasting and weakness, with a typical survival time of three to five years from onset…
Biosimilars│Emerging Biosimilars│Inflectra │U.S. Wave 1 is the first installment of a three-wave, syndicated report series, tracking physician perception and uptake of Pfizer/Celltrion’s…
This three-wave syndicated report series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for…
With its launch in August 2016, Zinbryta became the 14thdisease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody…
The rheumatoid arthritis (RA) therapy market has matured to the point that TNF-α inhibitors have become firmly established as first-line biological agents, leaving non-TNF-α inhibitor agents to…
Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary…
Multiple Sclerosis | Emerging Therapies | Zinbryta | US is a three-wave series that tracks the introduction of Zinbryta for the treatment of multiple sclerosis (MS). The series is based on primary…